OBJECTIVES The aim of this study was to evaluate dabigatran dual therapy versus warfarin triple therapy in patients with or without diabetes mellitus in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With
P atients with diabetes mellitus and coronary artery disease have a higher risk for major adverse cardiac events than patients without diabetes (1) (2) (3) . Patients with diabetes and atrial fibrillation (AF) also have a higher risk for ischemic stroke (4, 5) , and it was found in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial that also dabigatran-treated patients with combined AF and diabetes have a higher risk for both major bleeding events and thromboembolic events compared with those without diabetes (6) . Furthermore, in patients with AF, coronary artery disease was recently shown to be an independent risk factor for thromboembolic events, including ischemic stroke (7) . Patients with diabetes and AF who undergo percutaneous coronary intervention (PCI) may therefore have a particularly high risk of thromboembolic events. In the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran
Versus Triple Therapy With Warfarin in Patients
With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, dual-antithrombotic therapy with dabigatran was compared with triple-antithrombotic therapy with warfarin in patients with AF who underwent PCI (8) . The RE-DUAL PCI trial was powered for noninferiority for adverse bleeding events as well as thrombotic-related events using a composite of death, myocardial infarction, stroke, systemic embolism, and unplanned revascularization. While meeting its primary endpoints concerning bleeding and efficacy, it was further found, as part of formal hierarchical testing, that dabigatran 110 mg dual-antithrombotic therapy was superior to warfarin triple therapy with regard to bleeding events (8) . 
METHODS
The RE-DUAL PCI trial design, methods, and primary results have been published (8, 9) . A brief summary of design and methods is provided here. In the warfarin triple therapy group, aspirin was discontinued after 1 month in patients in whom bare-metal stents were implanted and after 3 months in patients in whom drug-eluting stents were implanted.
Randomization was performed with the use of Table 1 . Rates of previous stroke, PCI, and coronary artery bypass grafting were higher among patients with diabetes. Figure 2 , and the efficacyrelated endpoints are shown in Figure 3 . No interaction between treatment and diabetes subgroup could be detected, either for the bleeding or for the efficacy endpoints (Figures 2 and 3) .
In patients with diabetes, the risk for bleeding events was reduced by dabigatran 110 mg dual therapy (Figure 2 , Central Illustration). The bleeding reduction by dabigatran 110 mg dual therapy was numerically higher than that by dabigatran 150 mg In patients without diabetes, dabigatran 110 mg dual therapy and dabigatran 150 mg dual therapy were both found to reduce the risk for bleeding endpoints compared with warfarin triple therapy ( Figure 2) . The risks for the composite efficacy endpoint of DTE or unplanned revascularization were comparable for the dabigatran 110 mg dual therapy and dabigatran 150 mg dual therapy groups, respectively, versus the warfarin triple therapy group (Figure 3) .
DISCUSSION
In the RE-DUAL PCI trial, dabigatran dualantithrombotic therapy reduced bleeding events, without increasing the risk for major ischemic events, 3.0% per year) and the composite of stroke or systemic embolism (diabetes 1.9% vs. no diabetes 1.3% per year) were higher in patients with diabetes (12) . In comparison, our data suggest that patients with diabetes treated with oral anticoagulant therapy and 1 or 2 antiplatelet agents do not seem to have an increased risk for bleeding compared with patients without diabetes receiving similar medications. showing that dual therapy decreases the risk for bleeding events compared with triple therapy (8, (13) (14) (15) (16) (17) . The latest of these showed elegantly that the reduction of bleeding events with dual therapy with a novel oral anticoagulant agent (apixaban) and clopidogrel was due to both the omission of aspirin and the superiority of the novel oral anticoagulant over *This is subgroup analysis and thus not a priori powered for safety or efficacy. AF ¼ atrial fibrillation; PCI ¼ percutaneous coronary intervention. (6) . A RE-LY subgroup analysis suggested that concomitant antiplatelet use increased major bleeds by approximately 60% with a single antiplatelet agent, and major bleeds were more than doubled when dual-antiplatelet therapy was used (18) . The relative increase in bleeding risk in case of antiplatelet use was similar between the 2 dabigatran doses and warfarin, but the absolute rates of bleeding were lowest in patients treated with dabigatran 110 mg (18) . This information is important to tailor the treatment to the individual patient. In 2 recently updated consensus documents from both a European and a North American perspective, it was recommended that when dabigatran is used as part of dual therapy, the 150-mg dose should be used in patients considered to be at higher thrombotic risk, while the 110-mg dose can be considered in elderly patients and those with high bleeding risk (10, 19) . Our data support this strategy for patients without diabetes.
Among those with diabetes, however, dabigatran 110 mg dual therapy seems to reduce bleeding events to a greater extent than dabigatran 150 mg dual therapy compared with warfarin triple therapy, although the interaction p value was >0.05. Thus, because of the limitations of this subgroup analysis (see also the "Study Limitations" section), it is not fully clear if the results from the dabigatran 150 mg dual therapy versus warfarin comparison in the diabetic subgroup indicate a signal or are just a chance finding. Furthermore, the point estimates of the HR suggested comparable risk for the composite efficacy endpoint compared with warfarin triple therapy with the caveat that the RE-DUAL PCI study was not powered for subgroup analyses. STUDY LIMITATIONS. First, this was a subgroup analysis and consequently was powered neither for statistical comparisons between treatment groups nor for statistical interaction terms. Therefore, this subgroup analysis is generally to be regarded as an exploratory analysis, and observed results serve for signal detection and hypothesis generation. Thus, the absence of a statistically significant interaction between treatment and the diabetes subgroup does not necessarily imply consistency with the results obtained in the overall population. In contrast, no conclusions can be drawn purely on the results from the single subgroup categories.
Second, because of multiple statistical testing, it is possible that nominally statistically significant results may be a play of chance.
Third, intracranial hemorrhage and stent thrombosis were both rare events, and this subgroup analysis, as well as the main study, was not powered for individual endpoints. Nevertheless, we decided to report these events because of their major influence on clinical decision making.
Fourth, patients were randomized within 120 h after successful PCI and received open-label treatment, which according to guidelines included triple therapy and therefore aspirin from PCI to randomization (10, 19) . Periprocedural aspirin treatment is therefore still recommended.
Finally, our study included predominantly patients of male sex, and the outcomes may differ between men and women.
CONCLUSIONS
Dabigatran dual therapy had a lower risk for bleeding than warfarin triple therapy in patients with AF with or without diabetes following PCI. The point estimates of the HR also suggest a similar risk for the main composite efficacy endpoint, but one must keep in mind that the RE-DUAL PCI study was not powered for this efficacy endpoint in individual dose groups.
